

PATENT
Attorney Docket No. **UM-08477**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Shaomeng Wang *et al.***

Serial No.: 10/729,156

Group No.: 1614

Filed: 12/05/2003

Examiner:

Entitled: **Small Molecule Antagonists of BCL-2 Family Proteins**

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 26, 2005

By:


Mary Ellen Waite


Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

This Information Disclosure Statement is being filed before the issuance of an Office Action, therefore Applicant's believe no fee is required.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. **08-1290**. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: January 26, 2005


Robert A. Goetz
Registration No. 55,210

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shaomeng Wang *et al.*

Serial No.: 10/729,156

Group No.: 1614

Filed: 12/05/2003

Examiner:

Entitled: **Small Molecule Antagonists of BCL-2 Family
Proteins**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR§ 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on **January 26, 2005**.

By: _____

Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.


- U.S. Patent No. 3,647,791 issued to Rossi *et al.* on 03/07/72
- WO 97/40015 published on 30 October 1997
- WO 96/04250 published on 15 February 1996
- WO 94/20497 published on 15 September 1994
- Boyfield *et al.*, "n-(substituted-phenyl)piperazines:" Bioorganic And Medicinal Chemistry Letters, 6:1227-32 (1996)
- Rao, "Agents acting on the central nervous system. XIII:", Journal of Medicinal Chemistry 13:516-22 (1970)

- Singh *et al.*, "Antihypertensive and cns depressant properties of 3-(gamma-p-fluorobenzoylpropyl)2,3,4,4a,5,6-hexahydro-a)h)-pyrazinol(1-2-a)quinoline hydrochloride", *Experientia* 29:1529-30 (1973)
- Singh *et al.*, "Pharmacological studies on 3[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6,hexahydro-1-(H)pyrazinol(1,2,-a)quinoline hydrochloride (Compound 69/83)" *Arrzneimittel Forschung Drug Research* 28:1641-4 (1978)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: January 26, 2005

By: _____



Robert A. Goetz
Registration No. 55,210
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900



FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Attorney Docket No.: UM-08477		Serial No.: 10/729,156		
				Applicant: Shaomeng Wang <i>et al.</i>				
				Filing Date: 12/5/03		Group Art Unit:		
U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date	
	1	3,647,791	03/7/72	Rossi <i>et al.</i>	260	268	09/19/67	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	2	WO 97/40015	30 Oct 1997	PCT				
	3	WO 96/04250	15 Feb 1996	PCT				
	4	WO 94/20497	15 Sept 1994	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	5	Boyfield <i>et al.</i> , "n-(substituted-phenyl)piperazines:" Bioorganic And Medicinal Chemistry Letters, 6:1227-32 (1996)						
	6	Rao, "Agents acting on the central nervous system. XIII:," Journal of Medicinal Chemistry 13:516-22 (1970)						
	7	Singh <i>et al.</i> , "Antihypertensive and cns depressant properties of 3-(gamma-p-fluorobenzoylpropyl)-2,3,4,4a,5,6-hexahydro-1(h)-pyrazinol(1,-2-a)quinoline hydrochloride", Experientia 29:1529-30 (1973)						
	8	Singh <i>et al.</i> , "Pharmacological studies on 3[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6,hexahydro-1-(H)pyrazinol(1,2,-a)quinoline hydrochloride (Compound 69/83)" Arrzneimittel Forschung Drug Research 28:1641-4 (1978)						
Examiner:				Date Considered:				
EXAMINER:Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								